Rare cancers of the head and neck on behalf of the REFCOR, part 1

• Published in: Bulletin du cancer Vol. 110; no. 6; p. 692
• Main Authors: Chabrillac, Emilien, Even, Caroline, Costes-Martineau, Valérie, Fakhry, Nicolas, Digue, Laurence, Moya-Plana, Antoine, Baujat, Bertrand, Righini, Christian-Adrien, De Gabory, Ludovic, Verillaud, Benjamin, Vergez, Sébastien, Thariat, Juliette
• Format: Journal Article
• Language: English; French
• Published: France 01.06.2023
• Subjects: Head and Neck Neoplasms - pathology; Humans; Paranasal Sinus Neoplasms - pathology; Rare Diseases; Salivary Gland Neoplasms - pathology; Squamous Cell Carcinoma of Head and Neck - pathology; Sinonasal cancer; Tumeur rare; Rare tumor; Salivary gland cancer; Cancers salivaires; Expert; Network; Head and neck; Cancers naso-sinusiens; Tête et cou; Réseau; Expertise
• ISSN: 1769-6917
• DOI: 10.1016/j.bulcan.2023.04.008

Among the 16,000 new cases of malignant tumors of the head and neck diagnosed in France each year, 10% are not conventional squamous cell carcinomas. These so-called rare cancers are distinguished by their presentation and patterns of failure, which is important to recognize in order to offer specific adapted management and maximize the chances of tumor control. These cancers can be rare by their histology, which determines their local invasiveness, and their hematogenous/nodal spread. Their diagnosis can be difficult and often requires comprehensive immunohistochemistry and genomic techniques. Expert pathology review is recommended in the cases of undifferentiated tumors, sarcomas and at the slightest diagnostic doubt. These rare cancers can also be rare by their anatomical location when arising from the paranasal sinuses, salivary glands and ear. Their location requires knowledge of their specific extension routes, and may call for a specific surgical technique (skull base endoscopic sinus surgery, extended total parotidectomy, etc.) and adapted radiotherapy to spare healthy organs surrounding the tumor. This article (part 1) discusses the diagnostic and therapeutic specificities of these rare cancers, and develops the recommendations of the French ENT Cancer Expertise Network (REFCOR) concerning rare epithelial tumors, i.e., salivary tumors, sinonasal tumors, variants of conventional squamous cell carcinomas, neuroendocrine carcinomas, malignant odontogenic tumors, and ear tumors. A second article (part 2) is focused on non-epithelial tumors (sarcomas, mucosal melanomas, lymphomas, tumors of uncertain or undetermined malignancy) and describes the organization and missions of the REFCOR.